Overview

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Status:
Terminated
Trial end date:
2018-11-19
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in adult participants with induced viral upper respiratory tract infections (URTI).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.